CTOs on the Move

Zavante Therapeutics

www.zavante.com

 
Zavante is a clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.zavante.com
  • 12670 High Bluff Dr
    San Diego, CA USA 92130
  • Phone: 858.705.2365

Executives

Name Title Contact Details

Funding

Zavante Therapeutics raised $35M on 03/29/2016

Similar Companies

Black Diamond Therapeutics

Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery Engine in Basel, Switzerland.

Advanced Pipetting Systems

Advanced Pipetting Systems is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Insite Vision

Insite Vision is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oyster Point Pharma

Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.

Angstrom Pharmaceuticals

Angstrom Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.